Agent Capital

Metagenomi Reports Business Updates and Second Quarter 2024 Financial Results - Declared development candidate MGX-001 for the treatment of hemophilia A;  plans to present 12-month NHP durability study data in September 2024 - All Wave 1 Ionis collaboration programs advancing in lead optimization, unlocking potential for multiple development candidate nominations in 2025  Achieved milestone from partner Affini-T related to Metagenomi licensed technology - Well capitalized with $299.9M in cash, cash equivalents and available-for-sale marketable securities at the end of Q2 2024; cash runway anticipated to support operating plans into 2027 https://lnkd.in/e62_VjQ4

Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Proposed merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for serious, rare genetic skin diseases for which there are no FDA-approved therapies. Combined company is expected to have approximately $80.5 million of cash and cash equivalents at closing, including approximately $78.9 million from an oversubscribed private financing with participation from a syndicate of leading healthcare-dedicated investors, which is expected to provide cash runway into the second half of 2027. Anticipated cash and cash equivalents are expected to fund combined company through multiple clinical trial milestones, including pivotal Phase 3 clinical trial results from a single-arm, baseline-controlled clinical trial of QTORIN™3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic lymphatic malformations currently being conducted under FDA's Breakthrough Therapy Designation and Fast Track Designation programs. QTORIN™ rapamycin has the potential to be the first approved therapy and standard of care in the U.S. for microcystic lymphatic malformations and cutaneous venous malformations, if approved. Source: Pieris Pharmaceuticals Link: https://lnkd.in/eZnW3r2Z

Vittoria Biotherapeutics, a clinical-stage cell therapy company, announces a recent publication by investigators at the University of Pennsylvania in the peer-reviewed journal, Science Immunology. The publication details the critical influence of CD5, a key immunomodulatory protein, on engineered T-cell therapies, which is the foundational basis of the company’s proprietary Senza5TMplatform. This technology, developed by the University of Pennsylvania and exclusively licensed to Vittoria, leverages the therapeutic potential of CD5 modulation to enhance the efficacy of CAR T-cell therapies and underscores its utility across multiple hematological and solid tumor animal models. To learn more in-depth about these approaches, which underline Vittoria’s Senza5TM platform, the full publication is available here: https://lnkd.in/eD4D7NmK. Source: Vittoria Biotherapeutics

Join John Glasspool, Venture Partner at Agent Capital, and Cartier Esham, Ph.D., Chief Scientific Officer at BIO (Biotechnology Innovation Organization) for a discussion of the 2024 BIOSECURE act. https://lnkd.in/eWvVn6js

https://lnkd.in/eSP9Wrjr

Congratulations Zenas

Join John Glasspool, Venture Partner at Agent Capital, and Cartier Esham, Ph.D., Chief Scientific Officer at BIO (Biotechnology Innovation Organization) for a discussion of the 2024 BIOSECURE act. https://lnkd.in/eWvVn6js

Agent Capital co-leads $47 Million in Series B-1 Extension for Cerevance to Advance Robust Clinical Pipeline

Congrats to Skyhawk Therapeutics for announcing a business development deal today with Ipsen. https://lnkd.in/gsERJP5f

Today, we announced topline results from our PREEMPT CRC Study, the largest clinical study to validate a blood-based test for the early detection of colorectal cancer. Read more in the press release here: https://lnkd.in/gr3PgG89